These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34095442)

  • 1. Who funds Alzheimer's disease drug development?
    Cummings J; Bauzon J; Lee G
    Alzheimers Dement (N Y); 2021; 7(1):e12185. PubMed ID: 34095442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposed agents in the Alzheimer's disease drug development pipeline.
    Bauzon J; Lee G; Cummings J
    Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The price of progress: Funding and financing Alzheimer's disease drug development.
    Cummings J; Reiber C; Kumar P
    Alzheimers Dement (N Y); 2018; 4():330-343. PubMed ID: 30175227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease drug development pipeline: 2020.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2020; 6(1):e12050. PubMed ID: 32695874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease drug development pipeline: 2021.
    Cummings J; Lee G; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2021; 7(1):e12179. PubMed ID: 34095440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease drug development pipeline: 2018.
    Cummings J; Lee G; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2018; 4():195-214. PubMed ID: 29955663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease drug development pipeline: 2023.
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2023; 9(2):e12385. PubMed ID: 37251912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of comprehensive Alzheimer's disease centers to address unmet national needs.
    Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM
    Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease drug-development pipeline: few candidates, frequent failures.
    Cummings JL; Morstorf T; Zhong K
    Alzheimers Res Ther; 2014; 6(4):37. PubMed ID: 25024750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease drug development pipeline: 2019.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2019; 5():272-293. PubMed ID: 31334330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life-science research within US academic medical centers.
    Zinner DE; Campbell EG
    JAMA; 2009 Sep; 302(9):969-76. PubMed ID: 19724044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Not Available].
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2024; 10(2):e12465. PubMed ID: 38659717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's drug-development pipeline: 2016.
    Cummings J; Morstorf T; Lee G
    Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.
    Goswami ND; Tsalik EL; Naggie S; Miller WC; Horton JR; Pfeiffer CD; Hicks CB
    Trials; 2014 Jan; 15():31. PubMed ID: 24450313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The costs of developing treatments for Alzheimer's disease: A retrospective exploration.
    Cummings JL; Goldman DP; Simmons-Stern NR; Ponton E
    Alzheimers Dement; 2022 Mar; 18(3):469-477. PubMed ID: 34581499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy.
    Giacalone NJ; Milani N; Rawal B; Catalano PJ; Nguyen PL; Schoenfeld JD; Tishler RB; Margalit DN
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):34-43. PubMed ID: 29970311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018.
    Turner B; Rajeshuni N; Tran EM; Ludwig CA; Tauqeer Z; Weeks B; Kinde B; Pershing S
    Am J Ophthalmol; 2020 Mar; 211():132-141. PubMed ID: 31730839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.